Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Cortegiani, Andrea ^a   Russotto, Vincenzo ^a   Maggiore, Alessandra ^a   Attanasio, Massimo ^a   Naro, Alessandro R ^a   Raineri, Santi Maurizio ^a   Giarratano, Antonino ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; MICAFUNGIN; NYSTATIN; PLACEBO;

CANDIDA; CONFIDENCE INTERVAL; CRITICALLY ILL PATIENT; DRUG INDUSTRY; FUNGAL COLONIZATION; HUMAN; MORTALITY; MYCOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; ADULT; CRITICAL ILLNESS; IMMUNOCOMPROMISED PATIENT; META ANALYSIS; MYCOSES;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84962783015     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004920.pub3     Document Type: Review

References (109)

1. Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesch YY. Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial. Infectious Diseases in Clinical Practice 2000;9(4):169-75. [EMBASE: 2000158943]
2. Albert M, Williamson D, Muscedere J, Lauzier F, Rotstein C, Kanji S, et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine 2014;40(9):1313-22. [PUBMED: 24981955]
3. ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000;283(15):1995-2002. [PUBMED: 10789668]
4. Beshey BN, Okasha AS, Eldin MEN. Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine 2014;50(1):93-8. [Science Direct S2090506813000572]
5. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Critical Care Medicine 1999;27(6):1066-72. [PUBMED: 10397206]
6. Garbino J, Lew D, Romand JA, Auckenthaler P, Suter P, Pittet D. Fluconazole prevents severe Candida spp infections in high-risk critically ill patients. A randomized, double-blind, placebo-controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September-1 October. Washington: American Society for Microbiology, 1997:Abstract LM-23b.
7. Garbino J, Lew DP, Romand JA, Hugonenet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine 2002;28(12):1708-17. [PUBMED: 12447512]
8. Giglio M, Caggiano G, Dalfino L, Brienza N, Alicino I, Sgobio A, et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care 2012;16(2):R57. [PUBMED: 22490643]
9. He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology 2003;9(11):2619-21. [PUBMED: 14606111]
10. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Critical Care Medicine 2003;31(7):1938-46. [MEDLINE: 12847386]
11. Leon A, Toubas D, Renard P, Suinat JL, Raclot P, Cousson J, et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie 1990;31(8):514-8. [PUBMED: 2089973]
12. Namikawa T, Kitagawa H, Yamatsuji T, Naomoto Y, Kobayashi M, Hanazaki K. Pre-emptive treatment of fungal infection based on plasma β-D-glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology 2013;28(9):1457-61. [PUBMED: 23574148]
13. NCT00048750 A phase 3, randomized, double-blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT00048750 2002.
14. NCT01122368 A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT01122368 2010.
15. Normand S, Francois B, Dardé ML, Bouteille B, Bonnivard M, Preux PM, et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine 2005;31(11):1508-13. [PUBMED: 16195905]
16. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al. MSG-01: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre-Emptive Therapy for Invasive Candidiasis (IC) in High-Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1-4; Dallas, Texas. 2011.
17. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al. MSG01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clinical Infectious Diseases 2014;58(9):1219-26. [PUBMED: 24550378]
18. Parizkova R, Cerny V, Dostal P, Truhlar A. The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece 2000;11(6):271-5. [EMBASE: 2001046296]
19. Parizkova R, Dostal P, Cerny V. Fluconazole prophylaxis of systemic candida infection in non-neutropenic critically ill patients: a prospective randomized study. Critical Care 1999;3(Suppl 1):P061. [PUBMED: PMC3301764]
20. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery 2001;233(4):542-8. [PUBMED: 11303137]
21. Sandven P, Qvist H, Skovlund E, Giercksky KE, NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Critical Care Medicine 2002;30(3):541-7. [PUBMED: 11990912]
22. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma-Injury Infection & Critical Care 1994;36(1):20-5. [PUBMED: 8295245]
23. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine 2008;149(2):83-90. [PUBMED: 18626047]
24. Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery 1987;122(2):147-51. [MEDLINE: 3545141]
25. Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma 1988;28(5):648-54. [MEDLINE: 3285017]
26. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine 1993;21(11):1635-42. [PUBMED: 8222677]
27. Aerdts SJ, van Dalen R, Clasener HA, Festen J, van Lier HJ, Vollaard EJ. Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen. Chest 1991;100(3):783-91. [PUBMED: 1889273]
28. Azoulay E, Timsit JF, Souweine B, Legriel S, Max A, Misset B, et al. Weekly high dose liposomal amphotericin B (L-AMB) in septic shock patients with multiple candida colonization: AMBIDEX study. Intensive Care Medicine. 22nd Annual Congress of the European Society of Intensive Care Medicine (ESICM). Vienna, Austria., 2011; Vol. 37, issue Suppl 1:S6-314. [PUBMED: 21905295]
29. Blair P, Rowlands BJ, Lowry K, Webb H, Armstrong P, Smilie J. Selective decontamination of the digestive tract: a stratified, randomized, prospective study in a mixed intensive care unit. Surgery 1991;110(2):303-10. [PUBMED: 1650036]
30. Daeem DA. Efficacy of prophylactic fluconazole in reducing candidemia in high risk nicu and picu patients. Archives of Disease in Childhood. 4th Congress of the European Academy of Paediatric Societies Istanbul Turkey., 2012; Vol. 97, issue Suppl 2:A380. [EMBASE: 71063264]
31. De Jonge E, Schultz MJ, Spanjaard l, Bossuyt PM Vroom MB, Dankert J, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362(9389):1011-6. [PUBMED: 14522530]
32. Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012;7(8):e42282. [PUBMED: 22879929]
33. Latif ADA, Abdel Sultan MH, Mohamed HE. Efficacy of Prophylactic Fluconazole in Reducing Candidemia in High Risk NICU and PICU Patients. Life Science Journal 2012;9(1):817-24. [Web of Science: 000306398400118]
34. Milanov SG, Georgiev G, Todorova V, Kozarov L, Milanov M. Efficacy and utility of a protocol for pre-emptive antimycotic therapy. Critical Care. 30rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium., 2010; Vol. 14, issue Suppl 1:70. [PubMed Central 2934516]
35. Milanov S, Todorova VT, Georgiev G, Milanov M. Empirical versus preemptive antimycotic therapy in terms of outcome benefit. Critical Care. 33rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 2013; Vol. 17, issue Suppl 2:84. [PubMed Cantral 3643104]
36. NCT00095316 Caspofungin Study for Fungal Infections in Adults in Critical Care Settings. clinicaltrials.gov/ct2/show/NCT00095316 2004.
37. NCT00099775 Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units. clinicaltrials.gov/ct2/show/NCT00099775 2004.
38. NCT00163111 A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. clinicaltrials.gov/ct2/show/NCT00163111 2005.
39. NCT00689338 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study (ICE). clinicaltrials.gov/ct2/show/NCT00689338 2008.
40. NCT01045798 Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067). clinicaltrials.gov/ct2/show/study/NCT01045798?sect=X7340156 2010.
41. NCT01524081 Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures. clinicaltrials.gov/ct2/show/NCT01524081 2012.
42. Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Peritoneal Dialysis International 2010;30(6):619-25. [PUBMED: 20634438]
43. Sorkine P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Critical Care Medicine 1996;24(8):1311-5. [PUBMED: 8706484]
44. Wang DH, Gao XJ, Wei LQ, Xia R, Li Q, Peng M, et al. The preemptive treatment of invasive Candida infection with reference of corrected colonization index in critically ill patients: a multicentre, prospective, randomized controlled clinical study. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009;21(9):525-8. [PUBMED: 19751559]
45. Chen Z, Yang CL, He HW, Zeng J. The clinical research of nystatin in prevention of invasive fungal infections in patients on mechanical ventilation in intensive care unit. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013;25(8):475-8. [PUBMED: 24021043]
46. Havlicek K, Cervinka V, Sakra L, Motycka V, Mencl K. Preemptive antimycotic treatment in critically ill patients in the Czech Republic. International Surgery 2008;93(4):244-6. [PUBMED: 19731862]
47. Havlícek K, Motycka V, Sákra L, Mencl K, Ninger V, Safusová L. Preemptive antimycotic therapy in critically ill patients. Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti 2003;82(2):67-71. [PUBMED: 12712902]
48. ISRCTN40372159 Effects of digestive decontamination by amphotericine B on Candida colonisation and on the risk of invasive candidiasis in a surgical intensive care unit: a prospective randomised study. www.isrctn.com/ISRCTN40372159 2002.
49. ACTRN12605000596606 Safety and efficacy of ambisome versus conventional amphotericin B in the treatment of patients with suspected or confirmed mycosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12605000596606 2005.
50. EudraCT number: 2012-003172-39. Micafungin-Deescalation study: Evalutating the rate of breakthrough infections of micafungin followed by fluconazole versus fluconazole (or other azoles) in febrile patients. www.clinicaltrialsregister.eu/ctr-search/trial/2012-003172-39/AT 2013.
51. NCT01773876 Empirical Antifungal Treatment in ICUS (EMPIRICUS). clinicaltrials.gov/ct2/show/NCT01773876 2012.
52. Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vésin A, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials 2013;14:399. [PUBMED: 24261608]
53. Austin N, McGuide W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD003850.pub4]
54. Austin N, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD003478.pub4]
55. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine 2013;39(12):2092-106. [PUBMED: 24105327]
56. Bassetti M, Righi E, Ansaldi F, Merelli M, Scarpato C, Antonelli M, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine 2015;41(9):1601-10. [PUBMED: 26077063]
57. Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD006343.pub2; PUBMED: 20166083]
58. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55. [PUBMED: 1303622]
59. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clinical Microbiology and Infection 2012;18 Suppl 7:19-37. [PUBMED: 23137135]
60. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Medicine 2005;31(11):1479-87. [PUBMED: 16172847]
61. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transplantation 2006;12(5):850-8. [PUBMED: 16628697]
62. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection 2012;18(Suppl 7):9-18. [PUBMED: 23137134]
63. D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E, Liberati A. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000022.pub3]
64. Dodds Ashley E, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy 2012;32(10):890-901. [PUBMED: 23033228]
65. Fekkar A, Dannaoui E, Meyer I, Imbert S, Brossas JY, Uzunov M, et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?. European Journal of Clinical Microbiology & Infectious Diseases 2014;33(9):1489-96. [PUBMED: 24715154]
66. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagnostic Microbiology and Infectious Disease 2009;64(4):402-7. [PUBMED: 19446982]
67. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clinical Infectious Diseases 2006;43(1):25-31.
68. McMaster University. GRADEpro GDT. www.gradepro.org. McMaster University, 2015.
69. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD000026.pub2]
70. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of stay and cost attributable to candidaemia. Journal of Infection 2009;59(5):360-5. [PUBMED: 19744519]
71. Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Critical Care 2011;15:R198. [PUBMED: 21846332]
72. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
73. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from www.cochrane-handbook.org.
74. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from www.cochrane-handbook.org.
75. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
76. Ho KM, Lipman J, Dobb GJ, Webb SA. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Critical Care 2005;9:R710-7. [PUBMED: 16280069]
77. Kett DH, Azoulay E, Echeverria PM, Vincent JL, EPIC II Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Critical Care Medicine 2011;39(4):665-70. [PUBMED: 21169817]
78. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clinical Infectious Diseases 2012;54(12):1740-6. [PUBMED: 22423135]
79. Kullberg BJ, Arendrup MC. Invasive Candidiasis. New England Journal of Medicine 2015;373(15):1445-56. [PUBMED: 26444731]
80. Lau AF, Kabir M, Chen SC, Playford EG, Marriot DJ, et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. Journal of Clinical Microbiology 2015;54(4):1324-30. [PUBMED: 25673797]
81. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2, 441 patients.. Antimicrobial Agents and Chemotherapy 2011;55(2):532-8. [PUBMED: 21078946]
82. Marino E, Gallagher JC. Prophylactic antifungal agents used after lung transplantation. The Annals of Pharmacotherapy 2010;44(3):546-56. [PUBMED: 20179260]
83. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Critical Care Medicine 1995;23(10):1638-52. [PUBMED: 7587228]
84. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Medicine 2009;35(9):1526-31. [PUBMED: 19357832]
85. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, the Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Critical Care 2010;14:R222. [PUBMED: 21143834]
86. Matthew M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy 2005;49(9):3640-5. [PUBMED: 16127033]
87. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. European Journal of Clinical Microbiology and Infectious Diseases 2007;26(4):271-6. [PUBMED: 17333081]
88. Pancreatic Group, Chinese Medical Association. Clinical diagnosis and classification standard of acute pancreatitis. Zhonghua Waike Zazhi 1997;35:773-5.
89. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. The American Journal of Medicine 2012;125(1):S2-S13. [PUBMED: 22196207]
90. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). Journal of Clinical Microbiology 2011;49(1):396-9. [PUBMED: 21068282]
91. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonisation and subsequent infections in critically ill surgical patients. Annals of Surgery 1994;220(6):751-8. [MEDLINE: 7986142]
92. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004291.pub2]
93. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-3)-b-D-glucan assay, Candida score, and colonization index. Critical Care 2011;15:R249. [PUBMED: 22018278]
94. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clinical Microbiology and Infection 2014;20(4):O245-54. [PUBMED: 24125548]
95. Puig-Asensio M, Pemán J, Zaragoza R, Garnacho-Montero J, Martín-Mazuelos E, Cuenca-Estrella M, et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Critical Care Medicine 2014;42(6):1423-32. [PUBMED: 24557426]
96. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clinical Infectious Diseases 1998;27(4):781-8. [MEDLINE: 9798034]
97. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
98. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. Journal of Clinical Oncology 2007;25(34):5471-89. [MEDLINE: 17909198]
99. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
100. Schorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically-ill surgical patients: a meta-analysis. Critical Care Medicine 2005;33(9):1928-35. [PUBMED: 16148461]
101. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th Edition. Chichester, West Sussex, UK: Wiley, 2009.
102. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk surgical intensive care unit patients: a meta-analysis of randomized, placebo controlled trials. Critical Care Medicine 2006;34(4):1216-24. [MEDLINE: 16484923]
103. Vardakas KZ, Michalopoulos A, Kiriakidou KG, Siampli EP, Samonis G, Falagas ME. Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients. Clinical Microbiology and Infection 2009;15(3):289-92. [PUBMED: 19154488]
104. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 2009;302(21):2323-9. [PUBMED: 19952319]
105. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 2004;39(3):309-17. [PUBMED: 15306996]
106. Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database of Systematic Reviews 2016, Issue 1. [DOI: 10.1002/14651858.CD004920.pub3]
107. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically-ill patients. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004920]
108. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2]
109. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy 2006;25(9):549-61.